Silja Röttgers

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study

Andrea Biondi, Martin Schrappe, Paola De Lorenzo et al. · The Lancet Oncology · 2012 · 335 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

In Childhood Acute Lymphoblastic Leukemia, Blasts at Different Stages of Immunophenotypic Maturation Have Stem Cell Properties

Christoph le Viseur, Marc Hotfilder, Simon Bomken et al. · Cancer Cell · 2008 · 294 citations · Full text

Medicine, Hematology, Oncology +12

Minimal Residual Disease Values Discriminate Between Low and High Relapse Risk in Children With B-Cell Precursor Acute Lymphoblastic Leukemia and an Intrachromosomal Amplification of Chromosome 21: The Austrian and German Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster (ALL-BFM) Trials

Andishe Attarbaschi, Georg Mann, Renate Panzer‐Grümayer et al. · Journal of Clinical Oncology · 2008 · 111 citations · Full text

Medicine, Hematology, Oncology +17

Leukemic Stem Cells in Childhood High-Risk ALL/t(9;22) and t(4;11) Are Present in Primitive Lymphoid-Restricted CD34+CD19− Cells

Marc Hotfilder, Silja Röttgers, Annegret Rosemann et al. · Cancer Research · 2005 · 105 citations

Medicine, Hematology, Oncology +17

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

Giovanni Cazzaniga, Paola De Lorenzo, Julia Alten et al. · Haematologica · 2017 · 94 citations · Full text

Medicine, Hematology, Oncology +17